Evidence map›Paper›PMID 42706376›Full record

ArticleExperimental & molecular medicine2026

Immune pathway activation in gastric cancers with LINE-1 retrotransposon overexpression and homologous recombination deficiency.

Young Jin Kim, In-Pyo Baek, Bang Wool Eom, Min-Jung Seo, Heeyeon Joo, Yu Ri Choi, Min Kyoung Park, Jihye Oh, Boram Lee, Seung Min Ham and 16 more

Abstract read
In one paragraph

Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Young Jin Kim *Division of Genome Science, Department of Precision Medicine, National Institute of Health, Cheongju, Republic of Korea.
In-Pyo Baek *Department of Bioinformatics & Life Science, Soongsil University, Seoul, Republic of Korea.
Bang Wool EomNational Cancer Center, Goyang, Republic of Korea.
Min-Jung SeoNational Cancer Center, Goyang, Republic of Korea.
Heeyeon JooNational Cancer Center, Goyang, Republic of Korea.
Yu Ri ChoiNational Cancer Center, Goyang, Republic of Korea.
Min Kyoung ParkNational Cancer Center, Goyang, Republic of Korea.
Jihye OhNational Cancer Center, Goyang, Republic of Korea.
Boram LeeNational Cancer Center, Goyang, Republic of Korea.
Seung Min HamNational Cancer Center, Goyang, Republic of Korea.
Nak-Hyeon ChoiDivision of Genome Science, Department of Precision Medicine, National Institute of Health, Cheongju, Republic of Korea.
Seung-Pyo HongDepartment of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0002-6033-290X
Jaeyong ChoiGenomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, Republic of Korea.
Sookyung KimGenomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, Republic of Korea.
Seong-Ho KongDepartment of Surgery, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Republic of Korea.
Hyuk-Joon LeeDepartment of Surgery, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Republic of Korea.
Yun-Suhk SuhDepartment of Surgery, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Republic of Korea.
Jinhwa KongDivision of Genome Science, Department of Precision Medicine, National Institute of Health, Cheongju, Republic of Korea.
Je-Keun RheeDepartment of Bioinformatics & Life Science, Soongsil University, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0003-4811-8895
Sang-Won LeeDepartment of Chemistry and National Research Laboratory for Convergence Degradation Biology, Korea University, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0002-5042-0084
Hong Man YoonNational Cancer Center, Goyang, Republic of Korea.
Hark Kyun KimNational Cancer Center, Goyang, Republic of Korea. hkim@ncc.re.kr.
Young-Woo KimNational Cancer Center, Goyang, Republic of Korea. youngwookim@ncc.re.kr.
Jong-Il KimDepartment of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea. jongil@snu.ac.kr.ORCID http://orcid.org/0000-0002-7240-3744
Bong-Jo KimDivision of Genome Science, Department of Precision Medicine, National Institute of Health, Cheongju, Republic of Korea. kbj6181@korea.kr.
Han Kwang YangDepartment of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea. hkyang@ncc.re.kr.

Funding

Ministry of Health, Welfare and Family Affairs | Korea National Institute of Health (KNIH) 2019-NG-053-02, 2025-NI-002National Cancer Center (NCC) 24H1660, 24H1710, 24H1640, 24H1650, 25M2540, 25M3010 and 24H1640
6 · The paper itself

Abstract

There are only a few whole genome sequencing studies of human gastric cancer (GC) conducted so far. We performed comprehensive whole genome, bulk RNA, and methylation sequencing analyses of 100 samples of GC and adjacent normal tissue. In a smaller non-EBV/non-MSI subset (n = 23), we also performed proteomic profiling by mass spectrometry. We validated the proteomic findings in an independent dataset. Using this unprecedented dataset of human GC samples, we examined the extent of chromothripsis, homologous recombination deficiency, and retrotransposition, and correlated these events with patient outcomes. We found that chromothripsis occurred in 22% of GCs and correlated with poor prognosis. Multichromosomal chromothripsis was associated with a particularly high risk of death. Based on copy number (CN) signature analysis, we identified a distinct non-CN9 subgroup with significantly worse outcomes. Homologous recombination deficiency was present in 4% of GCs and was associated with overexpression of immune signaling pathways. Somatic retrotransposition events were most strongly associated with global hypomethylation. We also identified BYSL as a putative oncogenic driver within the 6p21 locus whose amplification is associated with poor prognosis. Collectively, our findings provide novel insights into the dysregulation of DNA stability and repair and their clinical relevance in human GCs.

Indexed as

Homologous RecombinationLong Interspersed Nucleotide ElementsStomach NeoplasmsDNA Copy Number VariationsDNA MethylationFemaleGene Expression Regulation, NeoplasticHumansPrognosisProteomicsSignal Transduction

Identifiers

PMID42706376
PMCPMC13633253

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.